HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer

The outlook for patients with advanced pancreatic cancer remains poor, despite significant advances in our understanding of pancreatic tumor biology. One emerging theme highlights the distinct composition of the pancreatic tumor microenvironment. Hyaluronic acid is a hydrophilic glycosaminoglycan wh...

Full description

Saved in:
Bibliographic Details
Published in:Future oncology (London, England) England), 2018-01, Vol.14 (1), p.13-22
Main Authors: Doherty, Gary J, Tempero, Margaret, Corrie, Pippa G
Format: Article
Language:English
Subjects:
Acids
Cell cycle
Chemotherapy
Cytotoxicity
Drug dosages
hyaluronan
Hyaluronic acid
hyaluronidase
Medical prognosis
Metastasis
Ovarian cancer
Pancreatic cancer
PEGPH20
Phase III trial
Prostate cancer
tumor microenvironment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The outlook for patients with advanced pancreatic cancer remains poor, despite significant advances in our understanding of pancreatic tumor biology. One emerging theme highlights the distinct composition of the pancreatic tumor microenvironment. Hyaluronic acid is a hydrophilic glycosaminoglycan whose production within the tumor leads to increased interstitial tumor pressure, thereby limiting the access of potentially effective circulating anticancer drugs via reduced tumor perfusion. PEGylated rHuPH20 is a multiply PEGylated recombinant human hyaluronidase that has shown promising efficacy in preclinical models and early phase clinical trials in pancreatic cancer patients. Here, we discuss these findings, and the rationale for the ongoing randomized Phase III trial (HALO-109-301), which seeks to definitively define the efficacy of PEGylated rHuPH20 alongside gemcitabine and nab-paclitaxel in previously untreated, hyaluronic acid-high, stage IV pancreatic cancer.
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2017-0338